Soleus Capital Management, L.P. is an SEC-registered investment adviser based in Greenwich, CT that reports managing 1 hedge fund on Form ADV. It reports $3.7 billion in regulatory assets under management. Its private funds, of all types, hold $3.8 billion in gross assets. Its disclosed U.S. stock holdings returned an estimated +25.8% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +90.5% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- $3.7 billionForm ADV Item 5.F
- Gross assets of private funds
- $3.8 billionAll private fund types, Form ADV
- Hedge funds managed
- 112 private funds in total
- Employees
- 23Form ADV Item 5.A
- Registration
- SEC-registered adviserCRD 294459
- Latest Form ADV
- 04/27/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +25.0% | +14.8% |
| Q1 2026 | +0.6% | -4.6% |
| Q4 2025 | +43.1% | +2.4% |
| Q3 2025 | +25.5% | +7.8% |
| Q2 2025 | -3.8% | +10.4% |
| Q1 2025 | -11.4% | -4.5% |
| Q4 2024 | -11.4% | +2.1% |
| Q3 2024 | +11.6% | +5.4% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.
13F holdings as of Sep 30, 2026
The 50 largest of 97 share positions ($2,813,021,888) reported by Soleus Capital Management, L.P. on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.
Share of the reported 13F portfolio, ten largest positions
- Krystal Biotech Inc13.47%
- Insulet Corp8.01%
- Novocure LTD5.34%
- TG Therapeutics Inc5.07%
- United Therapeutics Corp Del4.99%
- Celcuity Inc4.76%
- Rigel Pharmaceuticals Inc3.16%
- Inspire Med SYS Inc2.98%
- Erasca Inc2.66%
- Beta Bionics Inc2.53%
| Stock | Value | % of 13F portfolio | Shares | Shares vs prior quarter |
|---|---|---|---|---|
| Krystal Biotech Inc | $379,018,632 | 13.47% | 1,139,700 | +21.34% |
| Insulet Corp | $225,256,455 | 8.01% | 1,726,500 | +64.59% |
| Novocure LTD | $150,341,127 | 5.34% | 9,425,776 | -4.92% |
| TG Therapeutics Inc | $142,583,051 | 5.07% | 2,556,168 | -12.70% |
| United Therapeutics Corp Del | $140,349,510 | 4.99% | 259,000 | +14.81% |
| Celcuity Inc | $133,813,075 | 4.76% | 1,682,760 | -1.26% |
| Rigel Pharmaceuticals Inc | $88,764,718 | 3.16% | 1,843,504 | Unchanged |
| Inspire Med SYS Inc | $83,705,590 | 2.98% | 1,206,828 | -37.52% |
| Erasca Inc | $74,941,920 | 2.66% | 5,112,000 | +89.33% |
| Beta Bionics Inc | $71,055,692 | 2.53% | 3,743,714 | -14.79% |
| Ani Pharmaceuticals Inc | $70,870,075 | 2.52% | 975,500 | +12.42% |
| Vericel Corp | $62,379,928 | 2.22% | 1,554,059 | +6.50% |
| Geron Corp | $57,525,451 | 2.04% | 46,768,659 | +9.25% |
| Parabilis Medicines Inc | $54,392,892 | 1.93% | 1,684,512 | +14.98% |
| Argenx SE | $47,322,209 | 1.68% | 49,350 | +147.31% |
| Axogen Inc | $45,315,520 | 1.61% | 1,081,000 | +1,795.29% |
| Neuropace Inc | $44,279,680 | 1.57% | 3,218,000 | +10.54% |
| Evolus Inc | $40,720,000 | 1.45% | 5,090,000 | +518.90% |
| Zai Lab LTD | $40,642,620 | 1.44% | 1,543,000 | New |
| Progyny Inc | $39,850,580 | 1.42% | 1,582,000 | -1.25% |
| Trevi Therapeutics Inc | $39,061,051 | 1.39% | 2,727,727 | +131.24% |
| Nuvectis Pharma Inc | $36,129,097 | 1.28% | 1,710,658 | +71.07% |
| Edap TMS S A | $32,672,365 | 1.16% | 7,309,254 | Unchanged |
| Avalyn Pharmaceuticals Inc | $29,031,310 | 1.03% | 1,019,000 | +143.20% |
| Kodiak Sciences Inc | $27,204,377 | 0.97% | 286,966 | New |
| Silence Therapeutics PLC | $26,075,701 | 0.93% | 2,385,700 | +278.68% |
| Inhibikase Therapeutics Inc | $23,067,375 | 0.82% | 11,225,000 | +3.22% |
| Arcus Biosciences Inc | $22,265,460 | 0.79% | 862,000 | -26.25% |
| Legend Biotech Corp | $21,591,590 | 0.77% | 1,085,550 | -9.91% |
| Nurix Therapeutics Inc | $21,153,185 | 0.75% | 892,163 | -39.11% |
| Inhibrx Biosciences Inc | $21,016,800 | 0.75% | 210,000 | New |
| Adlai Nortye LTD | $20,357,680 | 0.72% | 1,272,355 | +213.76% |
| Palisade Bio Inc | $20,244,808 | 0.72% | 14,996,154 | +14.79% |
| Alkermes PLC | $20,167,047 | 0.72% | 497,706 | -51.64% |
| Tango Therapeutics Inc | $20,017,310 | 0.71% | 802,297 | +13.16% |
| Biodesix Inc | $19,921,518 | 0.71% | 667,835 | +13.97% |
| Pharvaris N V | $19,158,880 | 0.68% | 604,000 | -17.36% |
| Insmed Inc | $16,778,580 | 0.60% | 147,000 | +62.88% |
| Praxis Precision Medicines I | $16,458,863 | 0.59% | 56,515 | -68.16% |
| Jade Biosciences Inc | $16,451,538 | 0.58% | 1,170,928 | -24.49% |
| Kiniksa Pharmaceuticals Intl | $16,336,456 | 0.58% | 218,958 | -11.12% |
| Conmed Corp | $16,057,205 | 0.57% | 347,333 | New |
| Eton Pharmaceuticals Inc | $15,864,120 | 0.56% | 308,101 | New |
| Orthopediatrics Corp | $15,816,109 | 0.56% | 710,198 | -3.00% |
| Organogenesis Hldgs Inc | $15,482,303 | 0.55% | 11,300,951 | +11.44% |
| Grail Inc | $15,203,020 | 0.54% | 108,500 | New |
| MBX Biosciences Inc | $15,176,542 | 0.54% | 258,897 | -49.76% |
| Edgewise Therapeutics Inc | $13,397,472 | 0.48% | 329,987 | -26.81% |
| Amneal Pharmaceuticals Inc | $13,252,120 | 0.47% | 658,000 | New |
| Prelude Therapeutics Inc | $13,209,458 | 0.47% | 3,378,378 | Unchanged |
Changes since Jun 30, 2026
Comparing the share counts in the two quarter-end filings: 27 new positions, 27 sold out, 28 increased, 36 reduced and 6 unchanged.
Number of positions (a count, not dollars)
- New positions27
- Increased28
- Unchanged6
- Reduced36
- Sold out27
New positions
| Stock | Value | Shares |
|---|---|---|
| Zai Lab LTD | $40,642,620 | 1,543,000 |
| Kodiak Sciences Inc | $27,204,377 | 286,966 |
| Inhibrx Biosciences Inc | $21,016,800 | 210,000 |
| Conmed Corp | $16,057,205 | 347,333 |
| Eton Pharmaceuticals Inc | $15,864,120 | 308,101 |
| Grail Inc | $15,203,020 | 108,500 |
| Amneal Pharmaceuticals Inc | $13,252,120 | 658,000 |
| Sanofi SA | $11,338,250 | 275,000 |
| Tyra Biosciences Inc | $9,732,697 | 445,025 |
| Yarrow Bioscience Inc | $9,390,682 | 416,993 |
| Astrazeneca PLC | $8,477,175 | 52,500 |
| Revolution Medicines Inc | $7,440,470 | 36,249 |
| Castle Biosciences Inc | $5,014,598 | 141,137 |
| First Tracks Biotherapeutics | $4,979,320 | 140,500 |
| Glaukos Corp | $4,195,383 | 25,552 |
| Tcgx Acquisition Corp | $2,814,750 | 225,000 |
| Electra Therapeutics Inc | $2,812,500 | 250,000 |
| Waystar Hldg Corp | $1,267,000 | 50,000 |
| Mannkind Corp | $1,170,390 | 300,100 |
| Qiagen NV | $875,200 | 20,000 |
Sold out
| Stock | Value at Jun 30, 2026 | Shares held then |
|---|---|---|
| Globus Med Inc | $37,049,527 | 468,922 |
| Supernus Pharmaceuticals | $24,185,200 | 520,000 |
| Livanova PLC | $20,965,114 | 254,957 |
| Spyre Therapeutics Inc | $13,050,660 | 147,000 |
| Alnylam Pharmaceuticals Inc | $9,949,042 | 33,050 |
| Immunovant Inc | $9,709,560 | 252,000 |
| Nektar Therapeutics | $8,960,951 | 128,362 |
| Mirum Pharmaceuticals Inc | $8,780,250 | 75,000 |
| Artivion Inc | $8,718,360 | 388,000 |
| Enliven Therapeutics Inc | $8,408,108 | 165,677 |
| Sionna Therapeutics Inc | $7,816,451 | 177,687 |
| Immunic Inc | $6,916,500 | 450,000 |
| Merck & Co Inc | $6,425,000 | 50,000 |
| Relmada Therapeutics Inc | $5,827,374 | 842,106 |
| Structure Therapeutics Inc | $5,742,690 | 107,000 |
| Karyopharm Therapeutics Inc | $4,298,800 | 440,000 |
| Tectonic Therapeutic Inc | $3,495,388 | 101,684 |
| Arrivent Biopharma Inc | $1,737,000 | 50,000 |
| Corcept Therapeutics Inc | $1,708,828 | 19,653 |
| Veracyte Inc | $1,468,250 | 25,000 |
Largest increases
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Insulet Corp | +677,500 | +64.59% | $225,256,455 | 1,726,500 |
| Krystal Biotech Inc | +200,446 | +21.34% | $379,018,632 | 1,139,700 |
| Axogen Inc | +1,023,964 | +1,795.29% | $45,315,520 | 1,081,000 |
| Erasca Inc | +2,412,000 | +89.33% | $74,941,920 | 5,112,000 |
| Evolus Inc | +4,267,572 | +518.90% | $40,720,000 | 5,090,000 |
| Argenx SE | +29,395 | +147.31% | $47,322,209 | 49,350 |
| Trevi Therapeutics Inc | +1,548,109 | +131.24% | $39,061,051 | 2,727,727 |
| Silence Therapeutics PLC | +1,755,700 | +278.68% | $26,075,701 | 2,385,700 |
| United Therapeutics Corp Del | +33,413 | +14.81% | $140,349,510 | 259,000 |
| Avalyn Pharmaceuticals Inc | +600,000 | +143.20% | $29,031,310 | 1,019,000 |
| Nuvectis Pharma Inc | +710,658 | +71.07% | $36,129,097 | 1,710,658 |
| Adlai Nortye LTD | +866,832 | +213.76% | $20,357,680 | 1,272,355 |
| Ani Pharmaceuticals Inc | +107,740 | +12.42% | $70,870,075 | 975,500 |
| Parabilis Medicines Inc | +219,442 | +14.98% | $54,392,892 | 1,684,512 |
| Insmed Inc | +56,750 | +62.88% | $16,778,580 | 147,000 |
| Iovance Biotherapeutics Inc | +401,977 | +267.98% | $8,180,299 | 551,977 |
| Geron Corp | +3,960,000 | +9.25% | $57,525,451 | 46,768,659 |
| Neuropace Inc | +306,878 | +10.54% | $44,279,680 | 3,218,000 |
| Vericel Corp | +94,907 | +6.50% | $62,379,928 | 1,554,059 |
| Palisade Bio Inc | +1,932,467 | +14.79% | $20,244,808 | 14,996,154 |
Largest reductions
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Inspire Med SYS Inc | -724,608 | -37.52% | $83,705,590 | 1,206,828 |
| Indivior Pharmaceuticals Inc | -1,054,000 | -99.06% | $358,500 | 10,000 |
| Praxis Precision Medicines I | -121,002 | -68.16% | $16,458,863 | 56,515 |
| Unitedhealth Group Inc | -79,340 | -99.17% | $242,273 | 660 |
| Urogen Pharma LTD | -599,536 | -72.25% | $9,356,033 | 230,274 |
| Alkermes PLC | -531,546 | -51.64% | $20,167,047 | 497,706 |
| TG Therapeutics Inc | -371,727 | -12.70% | $142,583,051 | 2,556,168 |
| Avalo Therapeutics Inc | -1,271,384 | -76.82% | $5,880,496 | 383,594 |
| Syndax Pharmaceuticals Inc | -1,012,049 | -62.16% | $11,580,612 | 615,990 |
| Biomarin Pharmaceutical Inc | -254,452 | -67.75% | $7,267,200 | 121,120 |
| MBX Biosciences Inc | -256,382 | -49.76% | $15,176,542 | 258,897 |
| Nurix Therapeutics Inc | -573,000 | -39.11% | $21,153,185 | 892,163 |
| Sophia Genetics SA | -1,555,000 | -99.36% | $83,800 | 10,000 |
| Beta Bionics Inc | -650,000 | -14.79% | $71,055,692 | 3,743,714 |
| Vir Biotechnology Inc | -979,029 | -97.90% | $234,456 | 20,971 |
| Belite Bio Inc | -49,000 | -96.98% | $258,806 | 1,524 |
| Arcus Biosciences Inc | -306,738 | -26.25% | $22,265,460 | 862,000 |
| Novocure LTD | -487,625 | -4.92% | $150,341,127 | 9,425,776 |
| Tandem Diabetes Care Inc | -475,000 | -82.61% | $1,631,000 | 100,000 |
| Procept Biorobotics Corp | -402,642 | -40.14% | $10,938,523 | 600,358 |
Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.
From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures
Hedge funds filing Form D (2)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
Private equity funds filing Form D (3)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
Private funds reported on Form ADV (5)
As reported in the adviser's Form ADV filed Jul 3, 2024. Funds also listed from Form D are shown above.
Fund vehicles: feeder funds and single-deal vehicles (1)
Feeder funds invest through a master fund; single-deal vehicles (SPVs, co-investments, series) hold one investment.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures